Daniela Califano

10PUBLICATIONS
92CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 16, 2026
PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.

|Dec 19, 2025
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC.

Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino

|Nov 26, 2025
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer.

Riccardo Vida, Michele Bartoletti, Lucia Lerda

|Aug 21, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

Sara Santagata, Anna Maria Trotta, Crescenzo D'Alterio

|Dec 09, 2023
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.

Giovanni L Scaglione, Sandro Pignata, Angela Pettinato

|Sep 23, 2022
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.

Marina Fabbi, Delfina Costa, Daniela Russo

Pageof 2

Frequent Collaborators

5 joint publications

Sandro Pignata

5 joint publications

Daniela Russo

3 joint publications

Giovanni Luca Scaglione

3 joint publications

Paolo Chiodini